Researchers Submit Patent Application, "Peptide Used To Prevent Or Treat Synucleinopathy", for Approval (USPTO 20230242601).
In: Gene Therapy Weekly, 2023-08-25, S. 3971-3971
serialPeriodical
Zugriff:
The preventive or therapeutic agent according to claim 4, wherein the synucleinopathy is selected from the group consisting of Parkinson's disease, Lewy body disease, and multiple system atrophy. Amino Acids, Antibodies, Autonomic Nervous System Diseases and Conditions, Basal Ganglia Diseases and Conditions, Biotechnology, Blood Proteins, Brain Diseases and Conditions, Central Nervous System Diseases and Conditions, Drugs and Therapies, Health and Medicine, Immunoglobulins, Immunology, Movement Disorders, Multiple System Atrophy, Nerve Tissue Proteins, Nervous System Diseases and Conditions, Neurodegenerative Diseases and Conditions, Parkinson's Disease, Parkinsonian Disorders, Peptides, Primary Dysautonomias, Proteins, Synucleins, Therapeutics, Therapy, Tohoku University. [Extracted from the article]
Copyright of Gene Therapy Weekly is the property of NewsRx and its content may not be copied or emailed to multiple sites or posted to a listserv without the copyright holder's express written permission. However, users may print, download, or email articles for individual use. This abstract may be abridged. No warranty is given about the accuracy of the copy. Users should refer to the original published version of the material for the full abstract. (Copyright applies to all Abstracts.)
Titel: |
Researchers Submit Patent Application, "Peptide Used To Prevent Or Treat Synucleinopathy", for Approval (USPTO 20230242601).
|
---|---|
Zeitschrift: | Gene Therapy Weekly, 2023-08-25, S. 3971-3971 |
Veröffentlichung: | 2023 |
Medientyp: | serialPeriodical |
ISSN: | 1078-2842 (print) |
Sonstiges: |
|